Navigation Links
Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
Date:12/4/2008

AMSTERDAM, December 4 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that it has successfully completed treatment of the last patient on its ATIR(TM) phase I/II clinical trial. ATIR(TM), a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease (GvHD) and allow early immune reconstitution following a mismatched bone marrow transplantation. Nineteen end stage blood cancer patients were treated with no cases of grade III/IV acute GvHD occurring within the first 100 days after ATIR(TM) infusion, showing the feasibility and tolerability of the addition of ATIR(TM) in combination with a mismatched transplant procedure.

Following scientific advice from the EMEA Kiadis Pharma is preparing to initiate a multi center multinational pivotal study starting recruitment early 2009. In this study the efficacy of ATIR(TM) will be investigated in patients diagnosed with AML, ALL or MDS eligible for an allogeneic bone marrow transplantation but for whom no matching donor is available.

"Bone marrow transplantations are often the only treatment option left for end-stage blood cancer patients. But too many patients simply do not find a suitable matched donor in time" says Dr. Denis-Claude Roy of the Maisonneuve-Rosemont Hospital in Montreal, the principal investigator on the study. "Our study shows a rapid immune reconstitution in transplanted patients provided with ATIR(TM) treated immune cells from mismatched donors. Without ATIR(TM) treatment this would not be possible because of the high risk of acute Graft versus Host Disease with mismatched donor immune cells. This is obviously a very hopeful development for a large patient group."

Dr. Manja Bouman, CEO of Kiadis Pharma, says "The results of this clinical trial are very encouraging and it is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe an
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
2. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
3. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
4. Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand
5. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
6. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
7. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
8. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
9. Isogen Launches Major New Facility to Address Global Biopharma Demand
10. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
11. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... company with a focus on Omega-3 therapies for cardiovascular ... 2015 it issued 763,752 common shares of the Corporation ... interest for the period of December 5 th , ... outstanding Convertible Notes that is due on or before ...
(Date:3/26/2015)... , March 26, 2015 "Whether it,s ... patients one day." In a single sentence, ... chief scientific officer at Pfizer,s Centers for Therapeutic ... and scientists fueling progress at America,s biopharmaceutical companies. ... work side-by-side with academia, patient foundations and the National ...
(Date:3/26/2015)... ROYAL OAK, Mich. , March 26, 2015 /PRNewswire/ ... have performed the Midwest,s first commercial implant ... Drug Administration for patients with non-valvular atrial fibrillation. The ... to long-term use of blood-thinning warfarin medication to reduce ... the most common heart rhythm disorder affecting more than ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... Proprietary DNA delivery technology enables sustained,Interferon-beta production ... mouse model of heart disease, NEW ORLEANS--(BUSINESS ... Clinic and presented today at the American ... that a single,administration of DNA encoding the ...
... statins for only five weeks at,400 mg/week lowered ... with similarly favorable effects on other,atherogenic lipids, NEW ... Isis Pharmaceuticals, Inc. announced new,results from its Phase ... presented today at the of Cardiology,Annual Scientific Session ...
Cached Medicine Technology:Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 2Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... 2015 Emergency Medical Care (EMC), a ... Manhattan, recently commemorated its three-year anniversary of being the ... addition to 24-hour urgent care, Emergency Medical Care offers ... this time, Emergency Medical Care’s Urgent Care NYC ... pain, eye injuries, ear infections, fevers, insect bites, burns, ...
(Date:3/28/2015)... 2015 Centurion Service Group will be hosting ... April 2 at their Las Vegas warehouse, located at 4606 ... sale, which consists of equipment from hospitals and surgery centers ... a.m. PDT. , Buyers will find items of all ... are a one-stop-shop,” said Erik Tivin, CEO of Centurion. , ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... hip injuries is a growing field in orthopaedic medicine. ... with labral tear to confirm the pain etiology, research ... Medicine’s ( AOSSM ) Specialty Day suggests that pain ... outcomes following arthroscopic hip surgery. , “Our study ...
(Date:3/28/2015)... NC (PRWEB) March 28, 2015 Genomic ... with peritoneal mesothelioma, revealing, for the first time, key ... Click here to read the newly posted story ... at the University of British Columbia, the British Columbia ... genome mapping to reveal underlying molecular alterations and mutations ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... significant number of healthcare providers are using some form of complementary ... or they have introduced certain facets of alternative medicine into their ... ... 2008 -- As more consumers become aware of medical alternatives to ...
... decades, researchers have dreamed of creating robots with human-like abilities. Now ... and hand that moves and 'senses' like a human, and is ... far behind? , ... (PRWEB) July 23, 2008 -- ...
... provides permanent, natural looking results, says Dr. Michael Law a board ... into fat injections and the role of lipostructure in facial plastic ... provides natural beautiful and permanent results by restoring a youthful but ... ...
... Extraordinary Global Effort, Project Calls for ... 23 The Medpedia Project,today announced the ... of medicine called Medpedia. Physicians, medical schools,hospitals, ... now,volunteering to collaboratively build the most comprehensive ...
... tested, patient,s treatment and prognosis may be affected, study ... with stomach or pancreatic cancer may have more lymph ... treated at designated comprehensive cancer centers or at hospitals ... a U.S. study. , If too few lymph nodes ...
... of more than 16,000 members dedicated to promoting ... imaging and nuclear medicinehas awarded $170,000 in research ... research. The awards, supported by SNM,s Education and ... Meeting, held in New Orleans, La. , ...
Cached Medicine News:Health News:Eastern and Western Medicine Meet in Medical Offices 2Health News:Eastern and Western Medicine Meet in Medical Offices 3Health News:Eastern and Western Medicine Meet in Medical Offices 4Health News:Eastern and Western Medicine Meet in Medical Offices 5Health News:Sensitive, Smart and Strong - Too Bad it's Just a Robotic Arm 2Health News:Sensitive, Smart and Strong - Too Bad it's Just a Robotic Arm 3Health News:Sensitive, Smart and Strong - Too Bad it's Just a Robotic Arm 4Health News:Fat Grafting Provides Permanent, Natural Looking Results - Dr. Michael Law Explains Fat Injections as a New Trend in Facial Plastic Surgery 2Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 2Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 3Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 4Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 5Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 6Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 7Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 8Health News:More Cancer Lymph Nodes Analyzed at Specialty Centers 2Health News:Seeding the future: SNM grants grow molecular imaging and nuclear medicine research 2Health News:Seeding the future: SNM grants grow molecular imaging and nuclear medicine research 3
... synthetic porous ceramic graft material composed of Tricalcium ... that comprises 70% of human bone. TCP is ... allows the attachment of bone forming cells and ... granules as well as between each granule. Conduit ...
Schuknecht-Weitlaner retractor, sharp, angled arms....
Weitlaner Beckmann retractor, sharp prongs, SS....
Scoville sharp curette, 10, straight, scoop size 4 x 10 mm....
Medicine Products: